These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1218 related items for PubMed ID: 30481203

  • 21. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
    Saitoh Y, Bureta C, Sasaki H, Nagano S, Maeda S, Furukawa T, Taniguchi N, Setoguchi T.
    Mol Carcinog; 2019 Feb; 58(2):234-246. PubMed ID: 30303565
    [Abstract] [Full Text] [Related]

  • 22. The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
    Kim YS, Cha H, Kim HJ, Cho JM, Kim HR.
    Molecules; 2019 Jul 31; 24(15):. PubMed ID: 31370295
    [Abstract] [Full Text] [Related]

  • 23. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
    Ronan N, Bennett DM, Khan KA, McCarthy Y, Dahly D, Bourke L, Chelliah A, Cavazza A, O'Regan K, Moloney F, Plant BJ, Henry MT.
    Lung; 2018 Oct 31; 196(5):543-552. PubMed ID: 30066212
    [Abstract] [Full Text] [Related]

  • 24. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.
    Kwapiszewska G, Gungl A, Wilhelm J, Marsh LM, Thekkekara Puthenparampil H, Sinn K, Didiasova M, Klepetko W, Kosanovic D, Schermuly RT, Wujak L, Weiss B, Schaefer L, Schneider M, Kreuter M, Olschewski A, Seeger W, Olschewski H, Wygrecka M.
    Eur Respir J; 2018 Nov 31; 52(5):. PubMed ID: 30166321
    [Abstract] [Full Text] [Related]

  • 25. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M, Buhl L, Alsafadi HN, Klee S, Hermann S, Mutze K, Ota C, Lindner M, Behr J, Hilgendorff A, Wagner DE, Königshoff M.
    Respir Res; 2018 Sep 15; 19(1):175. PubMed ID: 30219058
    [Abstract] [Full Text] [Related]

  • 26. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
    Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, Watanabe J, Nagahama K, Okabe T, Hidayat M, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Sasaki S, Tominaga S, Takahashi K.
    Respir Res; 2019 Jun 11; 20(1):119. PubMed ID: 31185973
    [Abstract] [Full Text] [Related]

  • 27. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
    Ebrahimpour A, Ahir M, Wang M, Jegga AG, Bonnen MD, Eissa NT, Montesi SB, Raghu G, Ghebre YT.
    Sci Rep; 2022 Nov 30; 12(1):20668. PubMed ID: 36450789
    [Abstract] [Full Text] [Related]

  • 28. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B, Castiaux A, Van Simaeys G, Mathey C, Sherer F, Egrise D, Lacroix S, Huaux F, Doumont G, Goldman S.
    Respir Res; 2019 Jan 15; 20(1):10. PubMed ID: 30646908
    [Abstract] [Full Text] [Related]

  • 29. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A, Asano T, Isono M, Ito K, Asano T.
    BMC Urol; 2014 Aug 30; 14():71. PubMed ID: 25176354
    [Abstract] [Full Text] [Related]

  • 30. Therapeutic role of histone deacetylase inhibition in an in vitro model of Graves' orbitopathy.
    Byeon HJ, Choi SH, Kikkawa DO, Ko J, Yoon JS.
    Mol Med Rep; 2024 Dec 30; 30(6):. PubMed ID: 39329199
    [Abstract] [Full Text] [Related]

  • 31. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS, Habiel DM, Narayanan R, Jones I, Coelho AL, Murray LA, Jiang D, Noble PW, Hogaboam CM.
    Am J Respir Crit Care Med; 2018 Jun 01; 197(11):1443-1456. PubMed ID: 29634284
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A.
    Expert Rev Respir Med; 2010 Jun 01; 4(3):301-10. PubMed ID: 20524912
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
    Wang Y, Yella JK, Ghandikota S, Cherukuri TC, Ediga HH, Madala SK, Jegga AG.
    Ther Adv Respir Dis; 2020 Jun 01; 14():1753466620971143. PubMed ID: 33167785
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L, Cameli P, Perruzza M, Cekorja B, Bergantini L, d'Alessandro M, Refini RM, Pieroni M, Fossi A, Bennett D, Spalletti M, Mazzei MA, Sestini P, Rottoli P, Bargagli E.
    Ther Adv Respir Dis; 2020 Jun 01; 14():1753466620906326. PubMed ID: 32066332
    [No Abstract] [Full Text] [Related]

  • 39. Histone deacetylase inhibition downregulates collagen 3A1 in fibrotic lung fibroblasts.
    Zhang X, Liu H, Hock T, Thannickal VJ, Sanders YY.
    Int J Mol Sci; 2013 Sep 27; 14(10):19605-17. PubMed ID: 24084714
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 61.